Model Validity Range in Multicentre Clinical Trials

2001 ◽  
pp. 53-61
Author(s):  
V. Dragalin ◽  
V. V. Fedorov
Keyword(s):  
Clinical Trials ◽  
Model Validity ◽  
Validity Range

Continuous-time, high-cycle fatigue model: Validity range and computational acceleration for cyclic stress

2020 ◽  
Vol 136 ◽  
pp. 105582 ◽  
Author(s):  
Stefan B. Lindström ◽  
Carl-Johan Thore ◽  
Shyam Suresh ◽  
Anders Klarbring
Keyword(s):  
Continuous Time ◽  
High Cycle Fatigue ◽  
Cyclic Stress ◽  
Cycle Fatigue ◽  
Model Validity ◽  
Fatigue Model ◽  
Validity Range

Optimal design and the model validity range

1998 ◽  
Vol 72 (1-2) ◽  
pp. 215-227 ◽  
Author(s):  
Valery V. Fedorov ◽  
Grace Montepiedra ◽  
Christopher J. Nachtsheim
Keyword(s):  
Optimal Design ◽  
Model Validity ◽  
Validity Range

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

1973 ◽  
Vol 31 ◽  
pp. 404-405
Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Tumor Tissue ◽  
Soft Tissue Tumors ◽  
Clinical Usefulness ◽  
Electron Microscopic ◽  
Normal Cells ◽  
Electron Microscopic Autoradiography ◽  
Peritoneal Cells ◽  
Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Patients' satisfaction in clinical trials

2000 ◽  
Vol 248 (6) ◽  
pp. 441-442 ◽  
Author(s):  
L. Terenius
Keyword(s):  
Clinical Trials ◽  
Patients Satisfaction

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I

Clinical trials screening: An opportunity to increase medical care access

2001 ◽  
Vol 120 (5) ◽  
pp. A410-A410
Author(s):  
T KOVASC ◽  
R ALTMAN ◽  
R JUTABHA ◽  
G OHNING
Keyword(s):  
Clinical Trials ◽  
Medical Care ◽  
Care Access

The Payoffs and Pitfalls of Participating in Clinical Trials

2008 ◽  
Vol 39 (4) ◽  
pp. 53
Author(s):  
CAROLYN SACHS
Keyword(s):  
Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document